secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084142
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Septerna reports positive Phase 1 data for oral MRGPRX2 NAM SEP-631, plans Phase 2 in chronic spontaneous urticaria
--------------------------------------------------------------------------------

- SEP-631 well-tolerated; adverse event profile comparable to placebo across all doses studied
- Complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once daily
- Pharmacokinetic profile supports once-daily dosing with approximately 24-hour half-life
- Company plans Phase 2b trial in chronic spontaneous urticaria in the second half of 2026

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526084142/0001193125-26-084142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312526084142/d44190d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer